Capability Target 1.3: Protective Action Recommendations

ASSESSMENT – DEMONSTRATION AND EVALUATION GUIDANCE

By observing the OROs’ capability to address the appropriate bullet points below and while considering the overall capability being assessed, the following key points of review and associated questions should be considered and will support an evaluation of this capability target.

OROs demonstrate the capability to:

PLUME

  • Select and implement pre-planned precautionary protective actions.
    • Who, by title/position and organization, made decisions to implement any preplanned precautionary protective actions outlined within plans/procedures?
    • What precautionary protective actions were taken? Why?
  • Utilize the methodology in plans/procedures to select among a range of protective actions most appropriate in a given emergency. This could also include the use of preplanned precautionary protective actions contained in plans/procedures.
    • Were differences in dose projection greater than a factor of ten discussed with the licensee? If so, were the differences resolved, and timely and appropriately incorporated into the PAR?
  • Develop PARs.
    • Who, by title/position and organization, developed each PAR?
    • What information (e.g., from the licensee, field monitoring data, release data, meteorological data, etc.) was used to develop each PAR?
    • Were PARs based on the ECL?
    • Were ETEs considered?
    • Were EPA and FDA PAGs considered when making PARs? Was any other criteria, guidance, and/or  methodologies used?
    • Were recommendations for KI made and on what were they based?
    • What populations or groups were included in the KI PAR (e.g. general public, institutionalized)?
  • Transmit PARs in a timely manner.
    • Who, by title/position and organization, transmitted each PAR to the decision-makers?
    • Who was the PAR provided to?

POST-PLUME

  • Assess radiological consequences and provide appropriate PARs for the ingestion exposure pathway.
    • Who had the authority to make PARs for the ingestion pathway?
    • Were precautionary actions (e.g., placing animals on stored feed and water) were considered to protect the  ingestion pathway?
    • Did the ORO coordinate on PARs developed for ingestion pathway?
    • What boundaries were recommended for the restricted area? Did this include a recommendation for a buffer zone?
    • Were projected doses considered in developing recommendations for relocation? Were they compared to the  EPA PAGs?
    • Were FDA PAGs (DILs as a surrogate) considered when recommending holds or embargos?
    • Were recommendations made for exposure and dose limitations for those temporarily reentering the restricted area?
    • Were recommendations developed to assist decision-makers on relaxing protective actions to allow for return?